We further generated imatinib-resistant K562R cells, which is through the short-term induction of K562 cells with low dose of imatinib treatment, to determine the association of drug resistance of CML with TXNIP expression (Fig. 4F). Here, TXNIP is linked to chronic myelogenous leukemia, BCR-ABL1 positive.